Cognition no better on anti-dementia meds
Families and patients are thought to be increasingly requesting anti-dementia medications in the belief they will delay the onset of dementia, according to a Canadian study.
Researchers reviewed eight randomised trials that compared one of four drugs — donepezil, rivastigmine, galantamine or memantine — to placebo.
Although short-term cognitive benefits were identified on the Alzheimer’s Disease Assessment Scale, there was no long-term effect after 84 weeks.
No other benefits were identified on the Mini